Inspire (INSP) Q1 2026 Earnings Call Transcript

Inspire Medical Systems reported Q1 revenue of $204.6 million, up 1.6%, but cut full-year 2026 revenue guidance to $825 million-$875 million from prior expectations due to coding/reimbursement uncertainty and the WISER program. Management estimates these issues reduced Q1 revenue by about $20 million and could pressure the second quarter by $40 million-$50 million, with full-year headwinds of $120 million-$150 million. Despite improved operating margin, adjusted EBITDA margin of 17.5%, and $400 million of cash with no debt, the near-term outlook is softer and implies a 9%-11% annual revenue decline.

Analysis

The market is likely underestimating how much of this reset is procedural, not demand destruction. The near-term hit is being driven by reimbursement friction and authorization delays, which tend to create a one- to two-quarter timing shift rather than a permanent loss of patient demand; that matters because the company is explicitly managing a backlog of “hot leads.” If the new Medicare coding path becomes routinized and commercial payers stop forcing center-by-center improvisation, the revenue gap should compress faster than the lowered guide implies.

The bigger second-order effect is mix. Inspire V appears to be the strategic product, but the current billing confusion effectively taxes adoption by forcing centers to spend time on revenue cycle work instead of throughput; that disproportionately hurts newer accounts and smaller hospital systems with less sophisticated billing staff. In that setup, incumbents with cleaner reimbursement workflows and stronger field reimbursement teams can actually widen share while weaker centers defer implants or revert to the legacy system, creating a hidden consolidation effect in the installed base.

The contrarian take is that the selloff may be overdone if investors are extrapolating 2026 friction into 2027. This looks less like a failed launch and more like a delayed commercialization curve ahead of a potential CPT normalization in 2028; that gives the company a window to reaccelerate before the permanent code arrives. The real swing factor is not the headline C-code, but whether commercial prior auth conversion stabilizes; that is the leading indicator for whether second-half volumes inflect or the backlog keeps rolling.

On the risk side, the guidance still has meaningful downside skew because the Q2 impairment is larger than Q1 and the company is acknowledging uncertainty in both coding and GLP-1-related referral timing. If centers conclude that administrative complexity will persist into year-end, you could get a second wave of deferred procedures and a weaker-than-expected 2027 base. The balance sheet removes solvency risk, but not multiple compression if the market decides the growth algorithm has been structurally slowed.

Key Decisions for Investors

• Short INSP into any post-earnings bounce over the next 1-3 weeks; the setup is that Q2 likely shows the worst sequential revenue/operating margin pressure before any real operational proof points arrive.
• For a lower-risk expression, buy INSP Jan-2027 put spreads (or use bear put spreads around the current tape) to monetize the gap between management’s recovery narrative and the still-uncertain commercial prior-auth conversion curve.
• Pair trade: long a scaled, reimbursement-stable medtech payer-exposed winner versus short INSP for the next 2-3 months; the thesis is that INSP carries more idiosyncratic reimbursement risk than peers with mature coding pathways.
• If you want to own the eventual reacceleration, wait for evidence that Q3 prior authorizations inflect before going long; the clean trigger is improving authorization data, not the next conference call.
• Avoid chasing the stock until there is proof that the WISER drag is fading and commercial codings have normalized; otherwise the risk/reward remains asymmetric to the downside over the next two quarters.